Allworth Financial’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Allworth Financial’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-42	Closed	-$49	–	5068
2025 Q2	$49	Buy	+42	New	+$55	﹤0.01%	4452
2024 Q4	–	Sell	-293	Closed	-$1.08K	–	4053
2024 Q3	$1.08K	Hold	293	–	–	﹤0.01%	3193
2024 Q2	$1.08K	Buy	+293	New	+$3.27K	﹤0.01%	3136
2023 Q4	–	Sell	-7	Closed	-$141	–	3639
2023 Q3	$141	Sell	7 -1	-13%	-$25	﹤0.01%	3276
2023 Q2	$226	Buy	+8	New	+$192	﹤0.01%	3075
2023 Q1	–	Sell	-9	Closed	-$181	–	3309
2022 Q4	$181	Buy	9 +2	+29%	+$43	﹤0.01%	2804
2022 Q3	$0	Hold	7	–	–	﹤0.01%	3161
2022 Q2	$0	Buy	+7	New	+$185	﹤0.01%	2878

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Allworth Financial's ZNTL Position: Q3 2025 in Review

Allworth Financial sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2025, closing a stake of 42 shares — an estimated $49 sold.

Allworth Financial first reported a position in ZNTL in Q2 2022 and held it in 8 quarters. The position peaked at $1.08K in Q2 2024. 99 funds tracked by Wall St. Rank hold ZNTL as of Q3 2025.

Allworth Financial reported no remaining Zentalis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Allworth Financial sold 42 Zentalis Pharmaceuticals shares in Q3 2025, an estimated $49.
Allworth Financial first reported a position in Zentalis Pharmaceuticals in Q2 2022 and held it in 8 quarters.
Allworth Financial's Zentalis Pharmaceuticals position peaked at $1.08K in Q2 2024.
99 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2025.

Based on Allworth Financial's 13F filing for Q3 2025, filed 2 Dec 2025.